/	Q1	P.	E'	7	
				TO S	3
_	NUL	2	3 20	35 '	빙
Ŕ				4	ij
W.	À TE			ري	•
	V	ÌΑΩ	تنعط		

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Complete if Known **Application Number** 10/625,103 July 22, 2003 Filing Date Bailon First Name Inventor 1654 **Group Art Unit Examiner Name** Heard, Thomas S.

**Attorney Docket Number** Sheet of 21327 US2 **U.S. PATENT DOCUMENTS** U.S. Patent Document Name of Patentee or Applicant of Date of Publication of Examiner Cite Kind Code Cited Document Cited document Initials' No.' Number (if known) MM-DD-YYYY 2003/0125516 Bray, et. al. 07-03-2003 All Bartley, et. al. 08-18-1998 A12 5795569 FOREIGN PATENT DOCUMENTS Date of Publication of T Foreign Patent Document Name of Patentee or Cited Document Cite Examiner Kind Code<sup>5</sup> Office3 Number MM-DD-YYYY Applicant of Cited Document Initials' No.1 (if known)

Signature

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw life through citation if not in conformance and not considered. Include copy of this Signature

The community of the period of the period of the Emperor must precede the serial number of the period document. \* It is replaced to the document. The of the period of the period of the Emperor must precede the serial number of the period document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \* Applicant is to place a check mark here if English language Translation or abstract is ettached.

Examiner

Date Considered

	Substitute for form 1449A/PTO			or form 1449A/PTO	Complete if Known		
	010	MFOR	MAT	ION	DISCLOSURE	Application Number	10/625,103
	O I PINFORMATION DISCLOSURE STATEMENT BY APPLICANT				Y APPLICANT	Filing Date	July 22, 2003
/	UN 2 3 2005 (12) several sheets if necessary)					First Name Inventor	Bailon
						Group Art Unit	1654
			Examiner Name	Heard, Thomas S			
2	Sheet	2.5		Of	2	Attorney Docket Number	21327 US2

(RADEMA EN NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published Examiner Cite No. Initials' Contrled-Release, Pegylation, Liposomal Formulations: New **C3** Mechanism in the Delivery of Injectable Drugs (2000), Vol. 34, pp 915-923 Biomaterials 22, p. 405-417 (2001) "Review-Peptide and C4 protein PEGylation..." DATE Examiner **CONSIDERED** 

Signature CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw time through citation if not in conformance copy of this form with next communication to applicant.

Unique citation designation number. Applicant is to place a check mark here if English language Translation or abstract is attached.

158247.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

(Use several sheets if necessary)

Complete if Known				
Application Number	10/625,103			
Filing Date	July 22, 2003			
First Name Inventor	Bailon			
Group Art Unit				
Examiner Name				

21327 US2 Sheet of 1 Attorney Docket Number U.S. PATENT DOCUMENTS U.S. Patent Document Examiner Cite Name of Patentee or Applicant of Date of Publication of Kind Code Cited Document Cited document Initials' No.1 Number MM-DD-YYYY 5,464,933 Bolognesi, et. al. 11-07-1995 A1 5,955,422 Lin A2 09-21-1999 **A3** 6,015,881 Kang, et. al. 01-18-2000 A4 5,252,714 Harris, et. al. 10-12-1993 A5 5,672,662 Harris, et. al. 09-30-1997 **A6** 5,959,265 Van Ligten 09-28-1999 **A7** 5,990,237 Bentley, et. al. 11-23-1999 01-22-2002 **A8** 6,340,742 Burg, et. al. A9 6,348,568 Barney, et. al. 02-19-2002 A10 6,258,787 07-10-2001 Isner FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Publication of Cite Name of Patentee or Examiner Cited Document Office<sup>3</sup> Kind Code<sup>3</sup> Number<sup>4</sup> Initials' Applicant of Cited Document MM-DD-YYYY No.1 (if known)

	<u> </u>	١	
Examiner	17/1	7/	Date Considered
Signature		40	
SEVANTATED, Initial if of suppose and sidered substitute or not	citation is in application with MPED 600. Down tide the	-	stice if not in conformance and not considered. Include an

\*EXAMINENT: initial in research consistency, whether or and cause is in constitution as the constitution of the communication to applicant.

\*Unique citation designation number. \*See attached Kinds of U.S. Patent Documents. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation or abstract is attached.

Substitute for form 1449A/PTO	Compl	ete if Known
INFORMATION DISCLOSURE	Application Number	10/625,103
10 STATEMENT BY APPLICANT	Filing Date	July 22, 2003
	First Name Inventor	Bailon
(Use several sheets if necessary)	Group Art Unit	
The Triespier	Examiner Name	
. Sheet 2 . Of 2	Attorney Docket Number	21327 US2

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials'	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
7	Cl	Chem. Soc. Vol. 85, pg. 2149 (1963)	
	C2	Sheppard, R.C. et al., J. Chem. Soc. Chem. Comm. 165-166 (1985)	
<del>\</del>	-		
	ļ		
	-		
			ļ
	-		
	-		
	<u> </u>		
	-		
	ļ		
1		·	
			<b></b>
	<del>                                     </del>	<del> </del>	<del>                                     </del>
Examiner Signature	7	DATE CONSIDERED 2/2/0	>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance arguest copysidered. Include copy of this form with next communication to applicant.

\*Unique citation designation number. \*Applicant is to place a check mark here if English language Translation or abstract is attached.

135304

JUN 2 3 2015 E

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

(Use several sheets if necessary)

Complete if Known

Application Number 10/625,103

Filing Date July 22, 2003

First Name Inventor Bailon

Group Art Unit 1654

Examiner Name Heard, Thomas S.

of Attorney Docket Number 21327 US2 Sheet 1 **U.S. PATENT DOCUMENTS** U.S. Patent Document Date of Publication of Examiner Cite Name of Patentee or Applicant of Kind Code<sup>2</sup> Cited Document Cited document Initials' No.1 Number (if known) MM-DD-YYYY A11 2003/0125516 07-03-2003 Bray, et. al. 5795569 Bartley, et. al. 08-18-1998 A-12 FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Publication of Name of Patentee or Cited Document Cite Examiner Kind Code<sup>5</sup> Office3 Number Initials' Applicant of Cited Document MM-DD-YYYY No.1 (if known) Date Considered Examiner

Signature

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw life through citation if not in conformance and not considered. Include copy of this form with cert communication to anniform

\*Experiences: Install of reference considered, whether of that clearly is an obstance only of the form with next communication to applicant.

\*Unique citation designation number. \*See statched Kinds of U.S. Patent Documents. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation or abstract is attached.

Substitute for form 1449A/PTO	Complete if Known		
O I DINFORMATION DISCLOSURE	Application Number	10/625,103	
O I PINFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date	July 22, 2003	
(A)	First Name Inventor	Bailon	
UN 2 3 2005 (Cas several sheets if necessary)	Group Art Unit	1654	
	Examiner Name	Heard, Thomas S	
Sheet 2 Of 2	Attorney Docket Number	21327 US2	

CENT		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials'	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	C3	Contrled-Release, Pegylation, Liposomal Formulations: New	
122.		Mechanism in the Delivery of Injectable Drugs (2000), Vol. 34,	
		pp 915-923	
	C4	Biomaterials 22, p. 405-417 (2001) "Review-Peptide and	
1	İ	protein PEGylation"	
			·
	<del>                                     </del>		<b></b>
	<del> </del>		<b></b>
	<del> </del>		
	<del> </del>		
	ļ		ļ
			ļ
	<u> </u>		
•			
- <del>***</del> **			
S			
		P. 10.170	
			<del>                                     </del>
<u></u>	-		
	<del> </del>		<del> </del>
	ļ		<del> </del>
	L		
	<u> </u>		
Examiner Signature	4	DATE CONSIDERED 17/2/0	3
THE RESERVE THE PERSON NAMED IN COLUMN TWO IS NOT THE OWNER.			

\*EXAMINER: latital if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Unique citation designation number. \*Applicant is to place a check mark here if English language Translation or abstract is attached.

\*158247.

·-- ---- ;